-
Study aim
-
Evaluation of the therapeutic effect of Remdesivir on covid-19 patients referring to Ahvaz Jundishapur University of Medical Sciences hospitals,
A single-arm clinical trial study
-
Design
-
Single-arm clinical trial study, without control group, with a sample size of 50 people, , Phase 2_3 of Clinical trial
-
Settings and conduct
-
The place of the study is Ahvaz University of medical science hospitals, simple sampling of patients without randomization, without blinding, Single-arm clinical trial study, RemedSivir is used
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Age ≥18 years, Laboratory polymerase chain reaction (PCR) confirmed infection with COVID19, Severe pulmonary involvement in imaging, Oxygen saturation less than 90% with canola nasal or respiratory rate more than 30. Exclusion criteria: Treatment with other antiviral drugs not listed in the national protocol, Underlying disease, Allergic reaction to Remdesivir, Pregnant or lactating women, Possibility of transfer to another hospital, Evidence of multiple organ failure, Receive any experimental treatment for Covid 19, Patients under mechanical ventilation at the beginning of the study, Alanine Aminotransferase or Aspartate Aminotransferase more than 5 times normal, Creatinine clearance less than 50 ml per minute
-
Intervention groups
-
Main group: On the first day of treatment with RamedSivir with two 100 mg vials intravenously for 30 minutes to two hours and then 100 mg daily on the second, third, fourth and fifth days Takes. Each vial is prepared with 19 cc of distilled water and diluted with 0.9% saline.
-
Main outcome variables
-
Long of stay, oxygen saturation, fever, dyspnea, cough, Respiratory rate , lymphocyte blood count, C_ reactive protein, Alanine Amino Transferase, Aspartate Aminotransferase